Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).

@article{Spira2015EfficacySA,
  title={Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).},
  author={Alexander I. Spira and Keunchil Park and Julien Mazi{\`e}res and Johan Vansteenkiste and Achim Rittmeyer and Marcus D. Ballinger and Daniel Waterkamp and Marcin Kowanetz and Ahmad Mokatrin and Louis Fehrenbacher},
  journal={Journal of Clinical Oncology},
  year={2015},
  volume={33},
  pages={8010}
}

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 48 CITATIONS

Similar Papers

Loading similar papers…